Tan Li
Family Medicine · Lansing, MINPI 1417483918
Payments from drug & device makers
Across 96 payments — averaging $17.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$350
- Pfizer$297
- AstraZeneca$206
- Otsuka America Pharmaceutical, Inc.$178
- GSK$132
- Bayer$70
- plus $491 from 13 others
What the payments were for
- Food & beverage$1,70399%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 18 | $350 |
| Pfizer | 20 | $297 |
| AstraZeneca | 11 | $206 |
| Otsuka America Pharmaceutical, Inc. | 9 | $178 |
| GSK | 7 | $132 |
| Bayer | 4 | $70 |
| Lilly USA, LLC | 4 | $68 |
| AbbVie(2 entities) | 4 | $65 |
| Exact Sciences | 3 | $52 |
| Viatris Specialty LLC | 2 | $44 |
| Merck | 2 | $42 |
| Amgen | 2 | $36 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $36 |
| Mylan Specialty L.p. | 2 | $35 |
| Phadia US Inc. | 2 | $28 |
| Edwards Lifesciences | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Astellas Pharma US Inc | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
How this compares
$1,723 in reported general payments places this provider in the 75th percentile of 3,945 family medicine providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 143 | $132,355 |
| OzempicSemaglutide | 107 | $112,615 |
| MounjaroTirzepatide | 79 | $100,937 |
| EliquisApixaban | 73 | $73,020 |
| TrulicityDulaglutide | 34 | $50,854 |
| JardianceEmpagliflozin | 33 | $43,649 |
| RexultiBrexpiprazole | 18 | $25,422 |
| FarxigaDapagliflozin Propanediol | 19 | $23,794 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $22,995 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $16,727 |
| XareltoRivaroxaban | 16 | $13,354 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $10,597 |
| LinzessLinaclotide | 13 | $9,901 |
| Repatha SureclickEvolocumab | 14 | $8,606 |
| Advair HfaFluticasone Propion/Salmeterol | 13 | $8,033 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $68 | $151,791113 claims |
| GSKTrelegy Ellipta | $132 | $132,355143 claims |
| Novo NordiskOzempic | $350 | $112,615107 claims |
| PfizerEliquis | $297 | $73,02073 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $206 | $46,78942 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $178 | $25,42218 claims |
| AbbVieLinzess | $65 | $9,90113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Lansing
- Farhan BhattiLansing$230K
- David WeismantelLansing$180K
- Laurie RozekLansing$86K
- Amy TrinhLansing$19K
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.